Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

Related Keywords

Texas ,United States ,Timothya Yap , ,University Of Texas Md Anderson Cancer Center ,Investigational Cancer Therapeutics ,Cancer Medicine ,Cancer Center ,News ,Breast Cancer ,Conference ,Taacr ,Saruparib ,Hrr Mutations ,